RetroSense Therapeutics secures funding to support phase I/II trial of RST-001 Nov. 13, 2015 No Comments
Foundation Fighting Blindness provides funding to develop VM-200 for Stargardt disease Nov. 11, 2015 No Comments
RetroSense Therapeutics initiates phase I/IIa study of RST-001 gene therapy for retinitis pigmentosa Nov. 11, 2015 No Comments
European approval for Eylea for the treatment of visual impairment due to myopic CNV Nov. 3, 2015 No Comments
RSS